within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AJ05_Avacopan;
model Avacopan 
   extends Pharmacolibrary.Drugs.ATC.L.L04AJ05;

  annotation(Documentation(
    info ="<html><body><p>Avacopan is an orally administered selective C5a receptor antagonist used for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis, such as granulomatosis with polyangiitis and microscopic polyangiitis. Approved by regulatory authorities including the FDA (under brand name Tavneos) since 2021.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults, both healthy volunteers and patients with ANCA-associated vasculitis, after oral administration of avacopan at steady state.</p><h4>References</h4><ol><li><p>Miao, S, et al., &amp; Trivedi, A (2024). Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy Participants. <i>Clinical pharmacology in drug development</i> 13(9) 1011–1023. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1436&quot;>10.1002/cpdd.1436</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38993035/&quot;>https://pubmed.ncbi.nlm.nih.gov/38993035</a></p></li><li><p>Miao, S, et al., &amp; Trivedi, A (2024). Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Avacopan, a Small-Molecule Complement C5a Receptor Antagonist, for the Treatment of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Clinical pharmacology in drug development</i> 13(9) 1000–1010. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1444&quot;>10.1002/cpdd.1444</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38993026/&quot;>https://pubmed.ncbi.nlm.nih.gov/38993026</a></p></li><li><p>Miao, S, et al., &amp; Trivedi, A (2024). Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug-Drug Interaction of Avacopan in 2 Open-Label Studies in Healthy Participants. <i>Clinical pharmacology in drug development</i> 13(5) 517–533. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1389&quot;>10.1002/cpdd.1389</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38423992/&quot;>https://pubmed.ncbi.nlm.nih.gov/38423992</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Avacopan;
